The Wall Street Journal reports that Merck is creating a unit to make generic versions of biotech drugs. The story quotes CEO Richard Clark as saying, "We believe we can become the leading provider of high-quality, competitively priced follow-on biologics." One hurdle will be the lack of an FDA approval path for these biosimilars, but the article says that the incoming Obama administration has "raised expectations that Congress will clear the regulatory path as soon as next year."
If You Can't Beat 'Em...
Dec 11, 2008
What's Popular?